학술논문
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: A multiomics analysis
Document Type
Article
Author
Lo Russo, G.; Prelaj, A.; Beninato, T.; Ferrara, R.; Brambilla, M.; Occhipinti, M.; Mazzeo, L.; Provenzano, L.; Spagnoletti, A.; Manglaviti, S.; Giani, C.; Ambrosini, P.; Leporati, R.; Franza, A.; De Braud, F.; Proto, C.; Ganzinelli, M.; Garassino, M.C.; Miskovic, V.; Pedrocchi, A.L.G.; Trovo', F.; Dolezal, J.; Agnelli, L.; Fabbri, A.; Lorenzini, D.; Brich, S.; Torelli, T.; Pruneri, G.; Triulzi, T.; Viscardi, G.; Sgambelluri, F.; Anichini, A.; Mortarini, R.; McCulloch, J.; Trinchieri, G.; Torri, V.
Source
In: Journal for ImmunoTherapy of Cancer . (Journal for ImmunoTherapy of Cancer, 7 June 2023, 11(6))
Subject
Language
English
ISSN
20511426